Additional file 2 of Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

  • Alessia Visconti (Creator)
  • Niccolò Rossi (Creator)
  • Helena Deriš (Creator)
  • Karla A Lee (Creator)
  • Maja Hanić (Creator)
  • Irena Trbojević-Akmačić (Creator)
  • Andrew M. Thomas (Creator)
  • Laura Bolte (Creator)
  • Johannes Björk (Creator)
  • Jahlisa Hooiveld-Noeken (Creator)
  • Ruth Board (Creator)
  • Mark Harland (Creator)
  • Julia Newton-Bishop (Creator)
  • Mark Harries (Creator)
  • Joseph J. Sacco (Creator)
  • Paul C. Lorigan (Creator)
  • Heather M Shaw (Creator)
  • Liesbeth de Vries (Creator)
  • Rudolf Fehrmann (Creator)
  • Rinse Weersma (Creator)
  • Tim D. Spector (Creator)
  • Paul Nathan (Creator)
  • Geke Hospers (Creator)
  • Peter Sasieni (Creator)
  • Véronique Bataille (Creator)
  • Gordan Lauc (Creator)
  • Mario Falchi (Creator)

Dataset

Description

Additional file 2: Table 1. Description of total serum N-glycan UHPLC measured peaks. Table 2. Description of total serum derived traits. Table 3. Summary statistics for the associations between N-glycan traits and response to ICI treatment. Table 4. Summary statistics for the associations between N-glycan traits and progression-free survival. Table 5. Summary statistics for the associations between N-glycan traits and overall survival. Table 6. Summary statistics for the N-glycans shift at follow up with respect to the pre-treatment relative abundances.
Date made available18-Feb-2023
Publisherfigshare

Keywords on Datasets

  • Melanoma
  • Immune checkpoint inhibitors
  • Total serum N-glycomics
  • Response
  • Survival

Cite this